BioNTech (BNTX) announced that it has authorized a new share repurchase program under which the company may repurchase American Depositary Shares, each representing one ordinary share of the company, for an aggregate amount of up to $1B. Repurchases under the Program may be made until and including May 6, 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $158 from $171 at Canaccord
- BioNTech Maintained at Buy as Oncology Momentum Builds and Upside Seen at Unchanged $128 Price Target
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports
- BioNTech Posts Wider Q1 Loss as It Doubles Down on Oncology and Plans $1 Billion Buyback